Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

284 - Surgery versus Combined Surgery and Chemotherapy: Survival Patterns among Patients with Stage II Colorectal Adenocarcinoma

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Amany Shaltout

Citation

Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431

Authors

A.A. Shaltout1, N.M. Sayed1, A.Y. Abobakr1, R.E. Elemam1, I.O. Uthman2

Author affiliations

  • 1 Under Graduate, faculty of medecine suez canal university, 41511 - Ismailia/EG
  • 2 Under Graduate, Faculty of Medicine, Suez Canal University, 41511 - Ismailia/EG
More

Resources

Abstract 284

Background

In the United States, the incidence of developing colorectal cancer is < 5% in both males and females. The 5-year survival rates in stage IIA and IIB are 87% and 63% respectively. Surgery is the definitive treatment of stage II, while adding chemotherapy is still a debate. So we conducted this study to evaluate the efficacy of combined surgery and chemotherapy in the 5-year survival rates of stage II colorectal adenocarcinoma.

Methods

The data of 1231 patients with colorectal adenocarcinoma stage II from 2010 were collected using SEER database. There were 502 (41%) patients had combined chemotherapy and surgery, while 729 (59%) of them had surgery only. Patients’ demographics, carcinoembryonic antigen (CEA) test results, primary sites and sub stages of tumor were assessed.

Results

Patients with stage II colorectal adenocarcinoma who received combined surgery and chemotherapy had better 5-year relative survival rates (89%) than who went under surgery only (84.6%), (p-value <0.001). 5-year relative survival rates of combination were better in females (90.8%), negative CEA patients (93.4%), patients aged 20-40 years (100) and stage IIA (92.1%), (p-value <0.05). race and primary site of tumor were insignificant prognostic factors.

Table: 91P

VariablesSurvival of Patientsp value
CEA (carcinoembryonicantigen)

positive

Negative

81.9%

93.4%

<0.05*
Sex

Male

Female

87.3 %

90.8%

<0.05*
Age 20- 40

41- 60

61- 80

>80

100%

90.5%

87.9%

46.5%

<0.0001**
Race White

Black

Others

89.2%

79.9%

92.6%

0.261

Primary Site Ceacum

Ascending colon

Transverse colon

Splenic flexure

Descending colon

Sigmoid colon

Rectosigmoid junction

Rectum

74.5%

88%

91.9%

100%

89.8%

92.4%

86.8%

88.5%

0.661
Stage

IIA

IIB

IIC

92.1%

76.2%

63.4%

<0.0001**
**

Highly significant P-value ≤ 0.001

*

significant P-value <0.05

Conclusions

combined surgery and chemotherapy have better 5-year survival rates compared with surgery alone especially in those who are females, or have negative CEA test, aged 20-40 years or at stage IIA colorectal adenocarcinoma.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Faculty of Medicine Suez Canal University.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.